Abstract
Hypoxic-ischemic encephalopathy (HIE) is one of the most frequent causes of brain injury in the newborn. From a pathophysiological standpoint, a complex process takes place at the cellular and tissue level during the development of newborn brain damage in the absence of oxygen. Initially, the lesion is triggered by a deficit in the supply of oxygen to cells and tissues, causing a primary energy insufficiency. Subsequently, high energy phosphate levels recover transiently (the latent phase) that is followed by a secondary phase, in which many of the pathophysiological mechanisms involved in the development of neonatal brain damage ensue (i.e., excitotoxicity, massive influx of Ca2+, oxidative and nitrosative stress, inflammation). This leads to cell death by necrosis or apoptosis. Eventually, a tertiary phase occurs, characterized by the persistence of brain damage for months and even years after the HI insult. Hypothermia is the only therapeutic strategy against HIE that has been incorporated into neonatal intensive care units with limited success. Thus, there is an urgent need for agents with the capacity to curtail acute and chronic damage in HIE. Melatonin, a molecule of unusual phylogenetic conservation present in all known aerobic organisms, has a potential role as a neuroprotective agent both acutely and chronically in HIE. Melatonin displays a remarkable antioxidant and anti-inflammatory activity and is capable to cross the blood-brain barrier readily. Moreover, in many animal models of brain degeneration, melatonin was effective to impair chronic mechanisms of neuronal death. In animal models, and in a limited number of clinical studies, melatonin increased the level of protection developed by hypothermia in newborn asphyxia. This review article summarizes briefly the available therapeutic strategies in HIE and assesses the role of melatonin as a potentially relevant therapeutic tool to cover the hypoxia-ischemia phase and the secondary and tertiary phases following a hypoxic-ischemic insult.
Highlights
According to the World Health Organization, for every day in 2015, 16,000 children aged under 5 died (World Health Organization [WHO], 2015)
Stem cell therapy of hypoxic-ischemic encephalopathy (HIE), exclusive or associated with hypothermia, is still requires clinical trials to determine, among others, the most effective type of cells, the optimal dose and the most appropriate administration period for obtaining the best therapeutic results. One of these works in progress in the recruitment phase (Study of hCT-MSC in Newborn Infants With Moderate or Severe HIE, NCT03635450) will include a sample of 6 infants of 36 or more weeks of gestation with moderatesevere HIE, treated with hypothermia and infusion of two doses of stromal mesenchymal cells derived from umbilical cord
Randomized controlled pilot trials evaluating melatonin as an adjuvant to hypothermia in HIE indicated that the melatonin/hypothermia group show a reduced number of seizures, less evidence of white matter injury and a lower rate of mortality without developmental or neurological abnormalities (Aly et al, 2015; Ahmad et al, 2018)
Summary
According to the World Health Organization, for every day in 2015, 16,000 children aged under 5 died (World Health Organization [WHO], 2015). Stem cell therapy of HIE, exclusive or associated with hypothermia, is still requires clinical trials to determine, among others, the most effective type of cells, the optimal dose and the most appropriate administration period for obtaining the best therapeutic results One of these works in progress in the recruitment phase (Study of hCT-MSC in Newborn Infants With Moderate or Severe HIE, NCT03635450) will include a sample of 6 infants of 36 or more weeks of gestation with moderatesevere HIE, treated with hypothermia and infusion of two doses of stromal mesenchymal cells derived from umbilical cord. As far as a potential therapy for HIE in newborns, melatonin has many advantages It crosses readily the blood-brain barrier, its antioxidant and anti-inflammatory effects are readily exerted and it has an excellent safety profile (Gitto et al, 2001, 2009; Welin et al, 2007; Foley and Steel, 2019)
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
